Advertisement

Topics

Companies Related to "A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis." [Most Relevant Company Matches] RSS

22:56 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis." found in our extensive corporate database of over 50,000 company records.

Showing "Pilot Study Fluconazole Plus Flucytosine Treatment AIDS Patients" Companies 1–25 of 6,800+

Relevant

AIDS Treatment Activists Coalition

The AIDS Treatment Activists Coalition (ATAC) is a national non-profit AIDS advocacy group working to end the AIDS epidemic by advancing research of HIV/AIDS. The organization brings together people with HIV/AIDS, government, industry and academia in matters affecting research, treatment and access. ATAC receives support from the pharmaceutical industry, on which it reports, and private donors. ...


The Body The Complete HIV/AIDS Resource

The Body's mission is to:Use the Web to lower barriers between patients and clinicians. Demystify HIV/AIDS and its treatment. Improve patients' quality of life. Foster community through human connection.

US Bioscience Incorporated

US Bioscience, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for patients with cancer and allied diseases such as AIDS. Currently, three of the Company's products are marketed by US Bioscience and its commercial partners: Ethyol® (amifostine) A selective cytoprotective agent for reduction of toxicities associated with cancer chemotherapy. Hexalen...


ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

New Jersey Women and AIDS Network

Established in 1988, New Jersey Women and AIDS Network (NJWAN) is the only statewide female-specific AIDS service organization in New Jersey. NJWAN provides comprehensive services to women infected with and affected by HIV/AIDS. Our mission is to provide health/wellness and education programs in an effort to reduce the spread of HIV infection in women; support the self-determination of women liv...

PointCare Technologies Inc.

A daily cocktail of anti-retroviral therapy drugs can slow dramatically the development of HIV/AIDS. However, regular, repeated CD4/CD4% testing in HIV-infected individuals (examining the CD4 cells, also known as T-helper cells, in the blood) is essential - first to determine when ART should be initiated and then to ensure that the treatment remains safe and effective. The PointCare NOW system is ...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

RESprotect GmbH

RESprotect GmbH from Dresden develops drugs that prevent induction of chemoresistance of tumor cells and enhance their chemosensitivity. This concept is worldwide without concurrence. The first drug RP101 significantly extended survival time of pancreas cancer patients in a clinical pilot study.

VIRalliance

VIRalliance develops and markets high added value services and products to help optimise drug discovery and patient treatment in the fields of infectious diseases and oncology.VIRalliance has a development portfolio of innovative predictive tests to aid the optimal treatment.PHENOSCRIPT™ is the first of these tests to be made available to the public. PHENOSCRIPT™ is a novel and rapid HIV phen...

Viral Genetics

Viral Genetics is developing immune-based therapies for the treatment of HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. The Company’s primary product candidate is VGV-1, an investigational therapy for the treatment of HIV/AIDS that has demonstrated an antiviral effect in clinical trials with an apparent immunological mechanism of action. VGV-1 is a suspension ...

Pilot Pharmaceuticals

Pilot Pharmaceuticals develops novel products to treat CNS disorders with unmet medical need and substantial market size. The Company takes candidate drugs from an early discovery stage into clinical development.Pilot Pharmaceuticals will license its products to pharmaceutical companies, allowing them to complete the clinical development, gain regulatory approval and market the product.Pilot Pharm...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Elizabeth Glaser Pediatric AIDS Foundation

The Elizabeth Glaser Pediatric AIDS Foundation is a global leader in the fight against pediatric HIV and AIDS, working in 17 countries to implement prevention, care, and treatment; to further advance innovative research; and to execute strategic and targeted global advocacy activities to bring dramatic change to the lives of millions of women, children, and families worldwide.

MAC AIDS Fund (MAF)

The MAC AIDS Fund, the heart and soul of MAC Cosmetics, was established in 1994 to support men, women and children affected by HIV/AIDS globally. MAF is a pioneer in HIV/AIDS funding, providing financial support to organizations working with underserved regions and populations. As the largest corporate nonpharmaceutical giver in the arena, MAF is committed to addressing the link between poverty an...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

ADVANCED VIRAL RESEARCH CORP

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), established in the mid-1980s, and headquartered in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing, and bringing to market new and effective therapies for many serious diseases and disorders. With the commitment of expert leadership and skilled research scientists, ADVR is ag...

AIDS United

The mission of AIDS United is to end the AIDS epidemic in the United States. We will achieve this goal through national, regional and local policy/advocacy, strategic grantmaking, and organizational capacity building. With partners throughout the country, we will work to ensure that people living with and affected by HIV/AIDS have access to the prevention ...

IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. In addition, IAVI conduct...

Lifebeat and AIDS Healthcare Foundation

Los Angeles-based AIDS Healthcare Foundation (AHF) is a global organization providing cutting-edge medicine and advocacy to more than 300,000 patients in 32 countries. AHF is the largest provider of HIV/AIDS medical care in the U.S. AHF opened it's first NYC Out of The Closet Thrift Store on Atlantic Avenue in Brooklyn in April 2013, offering free rapid HI...

National AIDS Memorial Grove

The mission of the National AIDS Memorial Grove is to provide a healing sanctuary by offering in perpetuity a public landscape for grieving, gathering and renewal and to keep the human tragedy of AIDS in the forefront of the national consciousness by honoring all lives touched by AIDS.

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...


More From BioPortfolio on "A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis."

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks